Biosimilars and Biobetters

This year's conference will focus on the current and future landscape of the biosimilars market and will allow input from key industry experts in the field to engage in meaningful and important discussions on how to accelerate drug development to market.

Be part of a major networking opportunity providing intimate interaction with your peers, where you will hear case studies, presentations and round table discussions on the key issues surrounding biosimilar commercial and manufacturing developments.

KEY SPEAKERS INCLUDE:

Global Head Generics, Thought Leadership, Alan Sheppard, IMS Health
Founder, Carsten Brockmeyer, Brockmeyer Biopharma GmbH
Regulatory Affairs Manager, Catherine Akers, Amgen Inc
CEO, Ineke Braat, Pan-Generika
Partner, Liz Fuller, Bird and Bird
INSERM Director of Research, Laboratory of Biotechnology and Applied Pharmacology, Michael Tovey, Ecole Normale Supérieure de Cachan
Chief Regulatory Officer, Executive Vice President, Global regulatory - Governmental Relations, Michel Mikhail, Fresenius Kabi
Senior Consultant, Peter Wittner, Interpharm Consultancy
Chairman, Richard Dicicco, Harvest Moon Pharmaceuticals
Legal Director, Sarah Faircliffe, Bird and Bird
Principal Scientist and Head Analytical Development, Sharma Alok, Lupin Laboratories Ltd
Medical Director, Steinar Madsen, Norwegian Medicines Agency
Head of Safety Biosimilars, Uwe Gudat, Merck Switzerland Limited
Managing Director, Victoria Fine, PSORIASENSE


EVENT HIGHLIGHTS:

Optimizing the commercial potential of biosimilars in Europe
The big guns are coming! ...how will the entry of originator companies impact the biosimilars industry
What is on the horizon ... Reviewing the opportunities and challenges for the biopharmaceutical industry
Christening day…but what shall we call you! Discussing the ongoing debate on naming biosimilars and many more.